Protalix BioTherapeutics (PLX) Income towards Parent Company (2010 - 2026)

Protalix BioTherapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $18.4 million for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 608.1% year-over-year to $18.4 million; the TTM figure through Mar 2026 stood at $16.9 million (up 105.41% YoY), while the FY2025 annual figure was -$5.2 million, down 169.99% from the prior year.
• Income towards Parent Company was $18.4 million for Q1 2026 at Protalix BioTherapeutics, up from -$4.3 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $18.4 million in Q1 2026 to a low of -$24.8 million in Q4 2023.
• Historically, Income towards Parent Company has averaged -$436705.9 across 5 years, with a median of -$2.3 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Income towards Parent Company tumbled 671.43% in 2023, then soared 608.1% in 2026.
• A 5-year view of Income towards Parent Company shows it stood at -$3.2 million in 2022, then sank by 671.43% to -$24.8 million in 2023, then jumped by 143.64% to $10.8 million in 2024, then plunged by 139.9% to -$4.3 million in 2025, then soared by 526.44% to $18.4 million in 2026.
• The last three Income towards Parent Company figures came in at $18.4 million (Q1 2026), -$4.3 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.